Benzodiazepine use in the United States

JAMA Psychiatry

Volumn 72, Issue 2, 2015, Pages 136-142

  Olfson, Mark ^a,b   King, Marissa ^c   Schoenbaum, Michael ^d  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c YALE SCHOOL OF MANAGEMENT   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE;

ADULT; AGED; ARTICLE; DESCRIPTIVE RESEARCH; DRUG USE; FEMALE; HUMAN; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PHARMACY; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; AGE; EPIDEMIOLOGY; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TIME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BENZODIAZEPINES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84922254453     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.1763     Document Type: Article

References (80)

1. Sonnenberg CM, Bierman EJM, Deeg DJH, Comijs HC, van TilburgW, Beekman AT. Ten-year trends in benzodiazepine use in the Dutch population. Soc Psychiatry Psychiatr Epidemiol. 2012;47(2):293-301.
2. Cunningham CM, Hanley GE, Morgan S. Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy. 2010;97(2-3):122-129.
3. Fourrier A, Letenneur L, Dartigues JF, Moore N, Bégaud B. Benzodiazepine use in an elderly community-dwelling population: characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol. 2001;57(5):419-425.
4. Martin JL, Sainz-Pardo M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21(7):774-782.
5. van BalkomAJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B. Ameta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997;185(8):510-516.
6. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: ameta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-1350.
7. Baldwin DS, Anderson IM, Nutt DJ, et al; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567-596.
8. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82(6):355-362.
9. Morgenthaler TI, Lee-Chiong T, Alessi C, et al; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders: an American Academy of Sleep Medicine report. Sleep. 2007;30 (11):1445-1459.
10. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, SateiaM. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
11. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159(1):5-11.
12. Voshaar RC, Couvée JE, van BalkomAJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213-220.
13. Rickels K, Schweizer E, CaseWG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines, I: effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47(10):899-907.
14. Fenton MC, Keyes KM, Martins SS, Hasin DS. The role of a prescription in anxiety medication use, abuse, and dependence. Am J Psychiatry. 2010;167 (10):1247-1253.
15. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality: Drug AbuseWarning Network, 2008: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
16. Substance Abuse and Mental Health Services Administration. Drug AbuseWarning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
17. Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345:e6231.
18. Smink BE, Egberts AC, Lusthof KJ, Uges DRA, de Gier JJ. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs. 2010;24 (8):639-653.
19. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 2004;3(5):485-493.
20. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med. 2004;164 (14):1567-1572.
21. RayWA, Griffin MR, DowneyW. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989; 262(23):3303-3307.
22. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics and sedatives and risk of fractures: effects of half-life. Calcif Tissue Int. 2008;82(1):34-43.
23. de Vries OJ, Peeters G, Elders P, et al. The elimination half-life of benzodiazepines and fall risk: two prospective observational studies. Age Ageing. 2013;42(6):764-770.
24. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J AmGeriatr Soc. 2012;60(4):616-631.
25. Fick DM, Cooper JW,Wade WE,Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-2724.
26. Maletta G, Mattox KM, Dysken M. Guidelines for prescribing psychoactive drugs in the elderly: part 1. Geriatrics. 1991;46(9):40-47.
27. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385-391.
28. American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine Dependence, Toxicity, and Abuse. Arlington, VA: American Psychiatric Publishing; 1990.
29. Hogan DB, Maxwell CJ, Fung TS, Ebly EM; Canadian Study of Health and Aging. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. Can J Clin Pharmacol. 2003;10 (2):72-77.
30. Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol. 2007;22(5):292-298.
31. Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf. 2009;18 (7):572-578.
32. Cascade E, Kalali AH. Use of benzodiazepines in the treatment of anxiety. Psychiatry (Edgmont). 2008;5(9):21-22.
33. Lagnaoui R, Depont F, Fourrier A, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol. 2004; 60(7):523-529.
34. van Hulten R, Teeuw KB, BakkerA, Leufkens HG. Initial 3-month usage characteristics predict longterm use of benzodiazepines: an 8-year follow-up. Eur J Clin Pharmacol. 2003;58(10):689-694.
35. MoloneyME, Konrad TR, Zimmer CR. The medicalization of sleeplessness: a public health concern. Am J Public Health. 2011;101(8):1429-1433.
36. Gorevski E, Bian B, Kelton CML, Martin Boone JE, Guo JJ. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009. Ann Pharmacother. 2012;46(4):503-512.
37. Gray SL, Penninx BWJH, Blough DK, et al. Benzodiazepine use and physical performance in community-dwelling older women. J AmGeriatr Soc. 2003;51(11):1563-1570.
38. Rickels K. Should benzodiazepines be replaced by antidepressants in the treatment of anxiety disorders? fact or fiction? Psychother Psychosom. 2013;82(6):351-352.
39. Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 2002;63(9):756-757.
40. Agency for Healthcare Research and Quality, MEPS-HC panel design and data collection process. http://meps. ahrq. gov/survey-comp/hc-data -collection. jsp. Date accessed February 5, 2014.
41. KingM, Essick C. The geography of antidepressant, antipsychotic, and stimulant utilization in the United States. Health Place. 2013;20:32-38.
42. Czaja AS, Valuck R. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf. 2012;21(9):997-1004.
43. SchumockGT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J Allergy Clin Immunol. 2012;130(2):368-375.
44. Pearson SA, Soumerai S, Mah C, et al. Racial disparities in access after regulatory surveillance of benzodiazepines. Arch Intern Med. 2006;166(5): 572-579.
45. Ashton CH. Benzodiazepines: How TheyWork and How toWithdraw. Newcastle upon Tyne, England, UK: New Castle University; 2002.
46. Woolcott JC, Richardson KJ,Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009; 169(21):1952-1960.
47. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28(4):384-391.
48. Meuleners LB, Duke J, Lee AH, Palamara P, Hildebrand J, Ng JQ. Psychoactive medications and crash involvement requiring hospitalization for older drivers: a population-based study. J Am Geriatr Soc. 2011;59(9):1575-1580.
49. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001;158(6): 892-898.
50. Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, BeekmanAT. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry. 2007;22(12):1194-1200.
51. Kan CC, Hilberink SR, BretelerMHM. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry. 2004;45(2):88-94.
52. Fenton MC, Keyes KM, Martins SS, Hasin DS. The role of a prescription in anxiety medication use, abuse, and dependence. Am J Psychiatry. 2010; 167:1247-1253.
53. Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry. 2006;28(5):374-378.
54. Manthey L, Giltay EJ, van Veen T, Neven AK, Zitman FG, Penninx BW. Determinants of initiated and continued benzodiazepine use in the Netherlands study of depression and anxiety. J Clin Psychopharmacol. 2011;31(6):774-779.
55. Luijendijk HJ, Tiemeier H, Hofman A, Heeringa J, Stricker BH. Determinants of chronic benzodiazepine use in the elderly: a longitudinal study. Br J Clin Pharmacol. 2008;65(4):593-599.
56. Jorm AF, Grayson D, Creasey H,Waite L, Broe GA. Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health. 2000;24(1):7-10.
57. Ancoli-Israel S. Sleep and its disorders in aging populations. Sleep Med. 2009;10(suppl 1):S7-S11.
58. National Institute for Clinical Excellence. Guidance on the Use of Zaleplon, Zolpidem and Zopiclone for the Short-term Management of Insomnia, Technology Appraisal 77. London, England: NICE; 2004.
59. Cook JM, Marshall R, Masci C, Coyne JC. Physicians' perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med. 2007;22(3):303-307
60. Everitt H, McDermott L, Leydon G, Yules H, Baldwin D, Little P. GPs' management strategies for patients with insomnia: a survey and qualitative interview study. Br J Gen Pract. 2014;64(619): e112-e119.
61. Sivertsen B, Nordhus IH, Bjorvatn B, Pallesen S. Sleep problems in general practice: a national survey of assessment and treatment routines of general practitioners in Norway. J Sleep Res. 2010; 19(1, pt 1):36-41.
62. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG. Anxiety disorders in older adults: a comprehensive review. Depress Anxiety. 2010;27(2):190-211.
63. van Dijk KN, de Vries CS, ter Huurne K, van den Berg PB, Brouwers JR, de Jong-van den Berg LT. Concomitant prescribing of benzodiazepines during antidepressant therapy in the elderly. J Clin Epidemiol. 2002;55(10):1049-1053.
64. Furukawa TA, Streiner DL, Young LT, Kinoshita Y. Antidepressant plus benzodiazepine formajor depression. Cochrane Database Syst Rev. 2001;3(2): CD001026.
65. Préville M, Bossé C, Vasiliadis HM, et al. Correlates of potentially inappropriate prescriptions of benzodiazepines among older adults: results from the ESA study. Can J Aging. 2012;31(3):313-322.
66. Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J AmGeriatr Soc. 2002;50(1):26-34.
67. van derWaals FW, Mohrs J, Foets M. Sex differences among recipients of benzodiazepines in Dutch general practice. BMJ. 1993;307(6900): 363-366.
68. Van der Heyden JHA, Gisle L, Hesse E, Demarest S, Drieskens S, Tafforeau J. Gender differences in the use of anxiolytics and antidepressants: a population based study. Pharmacoepidemiol Drug Saf. 2009;18(11):1101-1110.
69. Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry. 1992;53(suppl):4-7.
70. Martinsson G, Fagerberg I,Wiklund-Gustin L, Lindholm C. Specialist prescribing of psychotropic drugs to older persons in Sweden: a register-based study of 188,024 older persons. BMC Psychiatry. 2012;12:197.
71. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301(19):2005-2015.
72. Lamberg L. Despite effectiveness, behavioral therapy for chronic insomnia still underused. JAMA. 2008;300(21):2474-2475.
73. Cook JM, Biyanova T, Masci C, Coyne JC. Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. J Gen Intern Med. 2007;22(8):1094-1100.
74. Kang DY, Park S, Rhee CW, et al. Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health. 2012;45(4):219-226.
75. FinkleWD, Der JS, Greenland S, et al. Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J AmGeriatr Soc. 2011; 59(10):1883-1890.
76. Lai MM, Lin CC, Lin CC, Liu CS, Li TC, Kao CH. Long-term use of zolpidem increases the risk of major injury: a population-based cohort study. Mayo Clin Proc. 2014;89(5):589-594.
77. Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med. 2008;9(8):818-822.
78. Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98-107.
79. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract. 2011;61 (590):e573-e578.
80. Bursztajn HJ, Brodsky A. Ethical and legal dimensions of benzodiazepine prescription: a commentary. Psychiatr Ann. 1998;28(3):121-127.